Innocare Pharma Releases 2025 Earnings Forecast, Full-Year Revenue Expected to Soar Approximately 134%

Incyte Health (SSE code: 688428; HKEX code: 09969) today announced its preliminary financial results for the fiscal year ending December 31, 2025.

Based on preliminary calculations by the finance department, Incyte Health expects to generate revenue of approximatelyRMB 2.37 billion, representing an increase of about134%. Meanwhile, the company expects its net profit attributable to shareholders to turn profitable for the first time in 2025, reaching approximatelyRMB 630 million. This is mainly attributed to the continuous commercial scaling and revenue from global business development (BD).

With the continued growth in market share of orelabrutinib (brand name: InnoCare Pharma®) for its exclusive indication of marginal zone lymphoma (MZL), as well as the approval and launch of new indications for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and tafasitamab (brand name: Minuo®) becoming the first approved CD19 antibody in China to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL),InnoCare Pharma's pharmaceutical revenue is expected to achieve rapid growth in 2025.

In 2025, InnoCare Pharma continues to efficiently advance its 2.0 strategic goals, achieving a series of key developments in its core pipeline:

- Orelabrutinib received approval for first-line treatment of CLL/SLL and was included in the national medical insurance system, and was listed as a Level I recommendation in the 2025 edition of the Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines. Currently, all four major indications of orelabrutinib have been incorporated into the national medical insurance system, benefiting more patients; orelabrutinib has also been approved in Singapore for treating relapsed/refractory marginal zone lymphoma;

- Tafasitamab innovative therapy was approved for treating relapsed/refractory DLBCL patients.This marks the first CD19 antibody approved in China for treating R/R DLBCL.

– China’s first independently developed next-generation TRK inhibitor, zolotrectinib,(brand name: InnoCare Pharma®) was approved for marketing, indicated for adult and adolescent patients aged 12 years and above with solid tumors carrying NTRK fusion genes.

- Mesutoclax (ICP-248), the company’s self-developed BCL2 inhibitor, is advancing rapidly in two Phase III registration clinical trials. The pivotal Phase III clinical trial of mesutoclax in combination with orelabrutinib for first-line treatment of CLL/SLL is nearing completion of patient enrollment, while the registration clinical trial for treating BTK inhibitor-treated mantle cell lymphoma (MCL) is progressing swiftly. Clinical trials of mesutoclax for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are ongoing in China and globally. Mesutoclax has been granted Breakthrough Therapy Designation (BTD).This is the first BCL2 inhibitor in China to receive BTD designation.

The Phase III registrational clinical trial for the company's self-developed novel TYK2 inhibitor, soficitinib (ICP-332), for the treatment of moderate to severe atopic dermatitis (AD) has completed patient enrollment. Meanwhile, the Phase II clinical trial of soficitinib for the treatment of vitiligo has also completed patient enrollment. Clinical trials of soficitinib for the treatment of prurigo nodularis, urticaria, psoriasis, and others are progressing rapidly.

Patient enrollment for the Phase III registrational clinical trial of the company's self-developed novel TYK2 inhibitor ICP-488 for the treatment of psoriasis is nearing completion, while the Phase II clinical trial for the treatment of cutaneous lupus erythematosus (CLE) is advancing quickly.

A breakthrough has been achieved in the differentiated antibody-drug conjugate (ADC) platform developed by Nuokang Health.The first ADC innovative drug, ICP-B794, has entered clinical trials.